Abstract
Twenty-seven fully evaluable patients with advanced ovarian cancer and documented disease progression despite cytotoxic treatment were treated with mitozolomide (NCS-353451) 90 mg/m2 as a 1-h infusion once every 6 weeks. None of the patients responded, one had stabilization of disease for 4 months. Haema-tologic toxicity was the major side effect with a nadir or white blood cell counts around day 40. Two patients died with severe leukopenia and septic shock. We conclude that mitozolomide is not active in this poor-risk group of patients.
| Original language | English |
|---|---|
| Pages (from-to) | 663-665 |
| Number of pages | 3 |
| Journal | Acta Oncologica |
| Volume | 28 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1989 |
Keywords
- Advanced ovarian cancer
- Mitozolomide
- Phase II study
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Hematology
Fingerprint Dive into the research topics of 'Phase ii trial of mitozolomide in patients with advanced ovarian cancer: A study of the eortc gynecological cancer cooperative group'. Together they form a unique fingerprint.
Cite this
Neijt, J. P., van der Burg, M. E. L., Guastalla, J. P., George, M., Piccart, M., Vermorken, J., Carnino, F., & Rotmensz, N. (1989). Phase ii trial of mitozolomide in patients with advanced ovarian cancer: A study of the eortc gynecological cancer cooperative group. Acta Oncologica, 28(5), 663-665. https://doi.org/10.3109/02841868909092290